US12553046B1ActiveUtility

Composition for regulating production of interfering ribonucleic acid

66
Assignee: WYVERN PHARMACEUTICALS INCPriority: Feb 11, 2025Filed: Feb 11, 2025Granted: Feb 17, 2026
Est. expiryFeb 11, 2045(~18.6 yrs left)· nominal 20-yr term from priority
Inventors:THOMPSON BRADLEY G
C12N 15/113C12N 2310/141C12N 2750/14143C12N 15/86
66
PatentIndex Score
0
Cited by
54
References
4
Claims

Abstract

The embodiments of the present disclosure relate to decreasing the bioavailability of one or more target biomolecules by providing a composition that comprises a recombinant plasmid (RP) and one or more sequences of micro-interfering ribonucleic acid (miRNA). When the RP interacts with a target cell, it causes the target cell to upregulate production of the miRNA, which then decreases the bioavailability of the target biomolecule. In some embodiments of the present disclosure, the target biomolecule is an apolipoprotein.

Claims

exact text as granted — not AI-modified
The invention claimed is: 
     
         1 . A composition that comprises a recombinant plasmid (RP) comprising a sequence of nucleotides that is SEQ ID NO. 2. 
     
     
         2 . The composition of  claim 1 , wherein the RP is encapsulated in a protein coat, a lipid vesicle, or any combination thereof. 
     
     
         3 . A composition that comprises a recombinant plasmid (RP) comprising a sequence of nucleotides that is SEQ ID NO. 3. 
     
     
         4 . The composition of  claim 3 , wherein the RP is encapsulated in a protein coat, a lipid vesicle, or any combination thereof.

Join the waitlist — get patent alerts

Track US12553046B1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.